compound 9i

Compound 9i is a non-specific designation used in scientific literature to refer to several distinct small molecule research compounds. One version is a pyrimidine derivative that acts as a GPR119 agonist, showing potent activity in human GPR119-expressing cells and improving glucose tolerance and insulin secretion, making it a candidate for diabetes and obesity research. A second version is a thiazolyl-isoxazole derivative developed by researchers at Sir Parashurambhau College, which has demonstrated preclinical antimicrobial activity against pathogens such as Escherichia coli, Mycobacterium tuberculosis, and Candida albicans. A third version belongs to a library of 1,2,3-triazole-incorporated 1,3,4-oxadiazole-triazine derivatives and has been evaluated for in vitro anticancer activity against various cell lines, including prostate (PC3, DU-145), lung (A549), and breast (MCF-7) cancers.